Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Cost of goods sold | 1,950 | 4,679 |
| Research and development | 57,094 | 46,889 |
| Selling, general and administrative | 80,254 | 60,413 |
| Royalty expense | 24,816 | 12,425 |
| Total operating expenses | 164,114 | 124,406 |
| Operating loss | (36,915) | (42,674) |
| Other income, net: |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s SG&A?
- Travere Therapeutics, Inc. (TVTX) reported SG&A of $80.25M in Q1 2026.
- How has Travere Therapeutics, Inc.'s SG&A changed year-over-year?
- Travere Therapeutics, Inc.'s SG&A increased by 32.8% year-over-year, from $60.41M to $80.25M.
- What is the long-term trend for Travere Therapeutics, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s SG&A has grown at a 26.6% compound annual growth rate (CAGR), from $126.28M to $324.78M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Travere Therapeutics, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude